NC State Employees Lose GLP-1 Coverage: What to Do

If you're a North Carolina state employee counting on your health plan to cover a GLP-1 medication for weight loss, the news isn't good. North Carolina's treasurer has confirmed that the expected state budget will not restore coverage for GLP-1 weight-loss drugs, leaving a significant financial gap for state workers who rely on these medications.

This isn't just a budget headline. For the people affected, it's a real question about whether they can afford to stay on a medication that may be working for them, or whether they can access one at all.

What Happened to GLP-1 Coverage for NC State Employees

North Carolina previously excluded GLP-1 medications prescribed specifically for weight loss from its State Health Plan. That exclusion was never reversed. And despite ongoing discussions about the 2025-2026 state budget, the treasurer has signaled that the budget as expected will not include a restoration of that coverage.

This matters because the State Health Plan covers roughly 750,000 teachers, state workers, retirees, and their dependents. That's a large pool of people who may be dealing with obesity or weight-related health conditions, and who are now being told the cost of treatment falls entirely on them.

It's worth noting that some GLP-1 medications prescribed for type 2 diabetes, like Ozempic (semaglutide), may still be covered when the diagnosis code supports it. But for weight management specifically, coverage remains off the table.

Why States Are Pushing Back on GLP-1 Coverage

North Carolina is not alone. Multiple state employee health plans across the country have restricted or eliminated GLP-1 weight-loss drug coverage, and the reason comes down to one thing: cost.

Wegovy (semaglutide 2.4 mg) has a list price around $1,350 per month. Mounjaro and Zepbound (tirzepatide) are similarly priced. When you multiply that cost across even a fraction of a large state workforce, the annual price tag runs into the hundreds of millions of dollars.

North Carolina's State Health Plan estimated that covering GLP-1 drugs for weight loss could cost the plan over $800 million annually. For a state government managing a complex budget, that figure creates enormous hesitation, even when the clinical evidence for these medications is strong.

The tension here is real. These drugs work. The clinical trial data supporting significant weight loss with semaglutide and tirzepatide is well-established. But cost-effectiveness debates at the policy level often move more slowly than the science.

What This Actually Costs You Without Coverage

If you're a state employee who has been using a GLP-1 medication or wants to start one, losing coverage means paying out of pocket, unless you can find a lower-cost alternative.

Here's a realistic look at monthly costs without insurance:

Prices vary by pharmacy, provider, and dose. The compounded options reflect current telehealth provider pricing and depend on ongoing FDA shortage designations.

Your Practical Options If You're Affected

Losing coverage doesn't mean losing access. It means you need a strategy. Here are the most realistic paths forward.

1. Manufacturer Savings Programs

Both Novo Nordisk and Eli Lilly offer savings programs for their branded medications. If you have commercial insurance (not government-funded insurance), you may qualify for significant monthly discounts. Since state employee plans are technically commercial plans, some members may be eligible.

• Novo Nordisk's NovoCare program for Wegovy can reduce costs to as low as $0 for qualifying patients
• Eli Lilly's savings card for Zepbound offers similar support for those who qualify

Check eligibility directly on each manufacturer's website, as income thresholds and plan restrictions apply.

2. Compounded GLP-1 Medications Through Telehealth

While the FDA has classified semaglutide and tirzepatide as being in shortage (a designation that makes compounding legally permissible), licensed compounding pharmacies can produce these medications at significantly lower prices.

Many telehealth platforms now offer compounded semaglutide and tirzepatide with physician oversight included. Monthly costs through these platforms typically range from $150 to $500, depending on dose and provider.

This is a meaningful cost difference from branded alternatives. However, compounded medications are not FDA-approved as finished drug products, and the regulatory environment around compounding continues to evolve. Talk to your doctor before making this switch.

Check the Best Providers page at GLP-1.com for a current comparison of telehealth platforms offering GLP-1 prescriptions.

3. Appeal Through Your HR Department or Union

If you work through a union or have access to HR advocacy, it's worth raising the issue formally. Some state health plan decisions can be influenced by employee pressure over time, and building a record of requests matters. Ask your HR office specifically whether any exceptions exist for weight-related comorbidities like type 2 diabetes, hypertension, or sleep apnea, as those conditions may open different coverage pathways.

4. Ask About Oral Semaglutide

Rybelsus is an oral form of semaglutide approved for type 2 diabetes. It carries a lower list price than injectable Wegovy and is sometimes covered when a diabetes diagnosis is documented. It's not approved for weight loss specifically, but your doctor can advise whether it's appropriate for your situation.

How to Talk to Your Doctor About This

If your coverage has changed or is about to change, the conversation with your prescriber needs to happen sooner rather than later. Here are specific questions worth asking:

• Is my GLP-1 prescription coded for diabetes or weight management, and does that affect my coverage options under my state health plan?
• Would I qualify for a manufacturer patient assistance or savings program given my insurance type?
• Is compounded semaglutide or tirzepatide a safe and appropriate option for my specific health needs?
• Are there any over-the-counter or lower-cost interventions we should layer in while I manage medication costs?
• If I need to reduce my dose or pause treatment temporarily, what is the safest way to do that without losing progress?

Your doctor may not always be aware of every cost-saving option available. Coming prepared with specific questions helps move the conversation in a useful direction.

The Broader Implications for Public Employee Health Plans

North Carolina's decision reflects a pattern playing out in state capitols across the country. As GLP-1 medications become more widely recognized as effective treatments for obesity, the disconnect between clinical evidence and insurance coverage is becoming harder to ignore.

The American Academy of Obesity Medicine and other medical organizations have pushed for broader coverage, arguing that treating obesity reduces long-term costs tied to cardiovascular disease, diabetes, and joint replacement. North Carolina legislators and plan administrators are weighing those long-term savings against immediate budget pressures.

This debate is far from over. Several states have moved in the opposite direction, adding GLP-1 coverage after evaluating actuarial data. North Carolina may revisit this in future budget cycles, especially if the political or financial calculus shifts.

For now, though, the people affected need solutions that work today, not promises about future budget cycles.

What This Means for You Right Now

If you're a North Carolina state employee, this coverage decision is frustrating, but it doesn't have to be a dead end.

The most important step is to act before your current supply runs out. If you're already on a GLP-1 medication, talk to your prescriber now about your options. If you're considering starting one, understand that lower-cost pathways exist and are accessible with the right guidance.

Here's a quick summary of your immediate action steps:

• Contact your HR department or state health plan directly to confirm exactly what is and is not covered under your specific plan tier before assuming anything has changed
• Check eligibility for manufacturer savings programs through Novo Nordisk and Eli Lilly before assuming you will pay full price, since state employee plans may qualify as commercial coverage
• Ask your doctor about compounded alternatives if branded medications are unaffordable, and discuss whether that option is clinically appropriate for your situation
• Explore telehealth platforms that combine prescription access with ongoing medical support, often at a fraction of the cost of a traditional clinic visit
• Revisit your coverage situation if your health status changes, particularly if you develop or are diagnosed with type 2 diabetes or another condition that may trigger a different coverage pathway

The science on these medications continues to strengthen. The coverage landscape is slower to catch up, but it is moving. In states and employer plans where GLP-1 coverage has expanded, the driving factor has often been organized, consistent advocacy from employees and their physicians.

If this issue affects you, making your voice heard through your union, HR department, or elected representatives is worth doing, even if results take time.

The Bottom Line

The expected North Carolina budget is a setback for state employees who need GLP-1 medications for weight management. But between manufacturer savings programs, compounded medication options through telehealth, and the potential for coverage through a diabetes or metabolic health diagnosis, there are real alternatives to paying full list price.

You deserve medical care that addresses your health needs. Don't let a coverage gap be the final word on your options.

Visit GLP-1.com to compare trusted GLP-1 providers, find available GLP-1 coupons and savings, and get the information you need to make a confident, informed decision about your next steps. Always consult your physician before starting, stopping, or changing any medication.